


## Mivebresib

|                           |  |       |          |
|---------------------------|--|-------|----------|
| <b>Cat. No.:</b>          | HY-100015  |       |          |
| <b>CAS No.:</b>           | 1445993-26-9   |       |          |
| <b>Molecular Formula:</b> | C <sub>22</sub> H <sub>19</sub> F <sub>2</sub> N <sub>3</sub> O <sub>4</sub> S |       |          |
| <b>Molecular Weight:</b>  | 459.47   |       |          |
| <b>Target:</b>            | Epigenetic Reader Domain; Apoptosis  |       |          |
| <b>Pathway:</b>           | Epigenetics; Apoptosis   |       |          |
| <b>Storage:</b>           | Powder   | -20°C | 3 years  |
|                           |  | 4°C   | 2 years  |
|                           | In solvent   | -80°C | 6 months |
|                           |  | -20°C | 1 month  |



### SOLVENT & SOLUBILITY

|   |  |                          |           |           |            |            |
|---|--|--------------------------|-----------|-----------|------------|------------|
| <b>In Vitro</b>   | DMSO : 100 mg/mL (217.64 mM; Need ultrasonic)  |                          |           |           |            |            |
|   |  | Solvent<br>Concentration | Mass      | 1 mg      | 5 mg       | 10 mg      |
|   | <b>Preparing Stock Solutions</b>   | 1 mM                     |           | 2.1764 mL | 10.8821 mL | 21.7642 mL |
|   |  | 5 mM                     |           | 0.4353 mL | 2.1764 mL  | 4.3528 mL  |
| 10 mM   |  |                          | 0.2176 mL | 1.0882 mL | 2.1764 mL  |            |
| Please refer to the solubility information to select the appropriate solvent. |  |                          |           |           |            |            |
| <b>In Vivo</b>  | <ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline<br/>Solubility: ≥ 2.5 mg/mL (5.44 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline)<br/>Solubility: ≥ 2.5 mg/mL (5.44 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil<br/>Solubility: ≥ 2.5 mg/mL (5.44 mM); Clear solution</li> </ol> |                          |           |           |            |            |

### BIOLOGICAL ACTIVITY

|                                     |   |
|-------------------------------------|---|
| <b>Description</b>                  | Mivebresib (ABBV-075) is a potent and orally active bromodomain and extraterminal domain (BET) bromodomain inhibitor. Mivebresib binds to BRD4 with a K <sub>i</sub> of 1.5 nM <sup>[1]</sup> .   |
| <b>IC<sub>50</sub> &amp; Target</b> | IC <sub>50</sub> : 1.5 nM (BRD4) <sup>[1]</sup>   |
| <b>In Vitro</b>                     | Mivebresib inhibit DHT-stimulated transcription of AR target genes without significant effect on AR protein expression. In addition to blocking the transcription activation downstream of AR, Mivebresib is also a potent inhibitor of MYC and the |

---

TMPRSS2-ETS fusion proteins<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## CUSTOMER VALIDATION

- J Med Chem. 2020 Jul 9;63(13):7186-7210.
- Biochem Pharmacol. 2021 Feb 1;185:114435.
- Martin-Luther-Universität Halle-Wittenberg. Naturwissenschaftlichen Fakultät I. 2020 Dec.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. EJ Faivre et al. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA